Although not examined here, this enzalutamide-induced reduction in OPG may also serve to inhibit breast cancer progression and metastasis as OPG has also been associated with increased breast tumor grade and metastatic potential [50, 54]. This evidence concerns the gene TNFRSF11B and breast cancer.